Ana Marques1, Frédéric Dutheil2, Elodie Durand3, Isabelle Rieu3, Aurélien Mulliez4, Maria Livia Fantini3, Yves Boirie5, Franck Durif3. 1. Université Clermont Auvergne, NPsy-Sydo, CHU Clermont-Ferrand, Neurologie, F-63000 Clermont-Ferrand, France. Electronic address: ar_marques@chu-clermontferrand.fr. 2. Université Clermont Auvergne, CNRS, LaPSCo, Stress physiologique et psychosocial, CHU Clermont-Ferrand, Santé Travail Environment, WittyFit, F-63000 Clermont-Ferrand, France. 3. Université Clermont Auvergne, NPsy-Sydo, CHU Clermont-Ferrand, Neurologie, F-63000 Clermont-Ferrand, France. 4. CHU Clermont-Ferrand, Direction de la Recherche Clinique, F-63000 Clermont-Ferrand, France. 5. Université Clermont Auvergne, INRA, UNH, Unité de Nutrition Humaine, CHU Clermont-Ferrand, Service de Nutrition Clinique, CRNH Auvergne, F-63000 CHU Clermont-Ferrand, France.
Abstract
OBJECTIVE: To detect changes in glucose regulation in moderate to advanced Parkinson's disease (PD) patients in response to oral glucose intake. METHODS: Blood glucose and insulin kinetics during a 75-g Oral Glucose Tolerance Test (OGTT) were compared between 50 PD patients and 50 healthy controls (CT) matched for body mass index (BMI), age and sex. Potential relationships between changes in glucose kinetics and clinical parameters were analyzed including Parkinson's disease severity and autonomic function using SCOPA-AUT (Scales for Outcomes in Parkinson's disease, Autonomic dysfunction). RESULTS: Blood glucose was significantly higher at T90 (p = 0.04) and T150 (p = 0.01) in PD patients compared to healthy matched controls. Moreover, the total area under time curve (AUC) for the blood glucose levels was significantly higher in PD patients compared to healthy controls (1187 ± 229 vs 1101 ± 201 mmol min.l-1; p = 0.05). Simultaneously, no significant increase of insulin levels was observed in PD patients compared to controls. Higher blood glucose levels were associated with higher BMI (p < 0.001), female gender (p < 0.033), longer duration of PD (p = 0.001), lower dose of dopaminergic treatment (p = 0.023), and higher score of dysautonomia (p = 0.017). CONCLUSION: Glucose control is impaired in moderate to advanced non-diabetic PD patients, due to impaired adaptive insulin response which may be a novel non-motor consequence of PD associated dysautonomia.
OBJECTIVE: To detect changes in glucose regulation in moderate to advanced Parkinson's disease (PD) patients in response to oral glucose intake. METHODS:Blood glucose and insulin kinetics during a 75-g Oral Glucose Tolerance Test (OGTT) were compared between 50 PDpatients and 50 healthy controls (CT) matched for body mass index (BMI), age and sex. Potential relationships between changes in glucose kinetics and clinical parameters were analyzed including Parkinson's disease severity and autonomic function using SCOPA-AUT (Scales for Outcomes in Parkinson's disease, Autonomic dysfunction). RESULTS:Blood glucose was significantly higher at T90 (p = 0.04) and T150 (p = 0.01) in PDpatients compared to healthy matched controls. Moreover, the total area under time curve (AUC) for the blood glucose levels was significantly higher in PDpatients compared to healthy controls (1187 ± 229 vs 1101 ± 201 mmol min.l-1; p = 0.05). Simultaneously, no significant increase of insulin levels was observed in PDpatients compared to controls. Higher blood glucose levels were associated with higher BMI (p < 0.001), female gender (p < 0.033), longer duration of PD (p = 0.001), lower dose of dopaminergic treatment (p = 0.023), and higher score of dysautonomia (p = 0.017). CONCLUSION:Glucose control is impaired in moderate to advanced non-diabetic PDpatients, due to impaired adaptive insulin response which may be a novel non-motor consequence of PD associated dysautonomia.
Authors: Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip Journal: Front Immunol Date: 2022-05-18 Impact factor: 8.786
Authors: Vignayanandam Ravindernath Muddapu; S Akila Parvathy Dharshini; V Srinivasa Chakravarthy; M Michael Gromiha Journal: Front Neurosci Date: 2020-03-31 Impact factor: 4.677